149 Pm, 166 Ho, 161 Tb and 177 Lu conjugated to chemical agents (monoclonal antibodies, polypeptide, etc.) have the appropriate decay characteristics for imaging and therapeutic studies and conse-quently the potential to be useful in radiotherapy and diagnosis. These carrier-free radioisotopes can be produced by neutron irradiation of a lanthanide target followed by β − decay, and a post-erior radiochemical separation of the daughter radionuclide from macro-amounts of the parent target. In order to produce carrier free 149 Pm, 161 Tb, 166 Ho and 177 Lu for radiotherapy, with a ra-dionuclide purity of more than 99.9%, a device production was developed based on separation of Nd/Pm, Gb/Tb, Dy/Ho and Yb/Lu by extraction chromatography. Keywords 149 Pm, 161 Tb, 166 Ho, 177 Lu, Production
CITATION STYLE
Monroy-Guzman, F., Barreiro, F. J., Salinas, E. J., & Treviño, A. L. V. (2015). Radiolanthanides Device Production. World Journal of Nuclear Science and Technology, 05(02), 111–119. https://doi.org/10.4236/wjnst.2015.52011
Mendeley helps you to discover research relevant for your work.